Skip to main content
TransThera Sciences (Nanjing), Inc. logo

TransThera Sciences (Nanjing), Inc. — Investor Relations & Filings

Ticker · 2617 ISIN · CNE100006T02 HKEX Manufacturing
Open in API
Filings indexed 80 across all filing types
Latest filing 2025-07-10 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2617

About TransThera Sciences (Nanjing), Inc.

https://www.transthera.com

TransThera Sciences (Nanjing), Inc. is a clinical-stage, R&D-driven biopharmaceutical company focused on the discovery, development, and commercialization of innovative small molecule therapies. Established in 2014, the company employs a clinical demand-oriented approach to address diseases with significant unmet medical needs. TransThera's pipeline is dedicated to generating first-in-class, best-in-class, and highly differentiated treatments, primarily targeting therapeutic areas such as oncology, inflammatory diseases, and cardiovascular conditions.

Recent filings

Filing Released Lang Actions
New Arrangements on Dissemination of Corporate Communications to Registered Shareholders
Regulatory Filings Classification · 80% confidence The document is a shareholder notification dated 10 July 2025 concerning new arrangements under HKEX Listing Rule 2.07A for electronic dissemination of “Corporate Communications” (annual reports, interim reports, notices, circulars, etc.). It is not itself an annual or interim report, proxy statement, or earnings release. It does not present financial data or board changes, nor is it soliciting votes. Rather, it is a procedural announcement on how future corporate communications will be delivered, fitting the definition of a general regulatory announcement. Therefore, it best fits the fallback category “Regulatory Filings” (RNS).
2025-07-10 English
New Arrangements on Dissemination of Corporate Communications to Non-Registered Shareholders
Regulatory Filings Classification · 85% confidence The document is a letter to non-registered shareholders informing them of a new arrangement for electronic dissemination of “Corporate Communications” under the Hong Kong Listing Rules. It contains no financial results, meeting notices, vote results, or management discussion, nor does it present an actual report. Instead, it announces a change in how corporate documents will be published and how shareholders can request printed copies. This falls under a general regulatory announcement that does not neatly fit other specific categories, so it should be classified as a Regulatory Filing (RNS).
2025-07-10 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2025
Regulatory Filings Classification · 80% confidence The document is an HKEX Form FF301 “Monthly Return for Equity Issuer and Hong Kong Depositary Receipts” under the Exchange Listing Rules, detailing authorised and issued share movements. It is a routine regulatory compliance filing rather than an annual report, earnings release, management or governance report, or a specific transaction announcement. No actual share issuance or repurchase event is announced, and it is not an investor presentation or call transcript. Therefore, it falls under the fallback category for miscellaneous regulatory filings.
2025-07-07 English
VOLUNTARY ANNOUNCEMENT GRANT OF TINENGOTINIB (TT-00420) FAST TRACK DESIGNATION FOR TREATMENT OF MCRPC
Regulatory Filings Classification · 85% confidence The document is a voluntary business update by a Hong Kong-listed company announcing an FDA fast track designation for a drug candidate. It contains no financial results, no meeting materials, no management changes, no legal proceedings, and no requests for shareholder votes. It is not an earnings release or a report publication announcement but rather a general regulatory and operational milestone announcement. This falls under the fallback category for miscellaneous regulatory announcements.
2025-06-24 English
CLARIFICATION ANNOUNCEMENT
Share Issue/Capital Change Classification · 85% confidence The document is an announcement of final offer price and allotment results for TransThera Sciences’ global offering, detailing the number of shares issued, offer price, public and international allocations, and capitalization details. This is clearly a capital raising event involving new share issuance and related allotment information. It matches the definition of a Share Issue/Capital Change announcement (Code: SHA).
2025-06-22 English
ANNOUNCEMENT OF ALLOTMENT RESULTS
Share Issue/Capital Change Classification · 92% confidence The document is a formal announcement by TransThera Sciences (Nanjing), Inc. detailing the terms of its Global Offering (IPO): the number of H Shares offered, the final offer price, allotment results for the Hong Kong Public and International Offerings, cornerstone investors, lock-up undertakings, etc. This constitutes an announcement of a new share issue and related capital structure changes. Therefore, it falls squarely under “Share Issue/Capital Change” (SHA).
2025-06-20 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.